Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM6A | O15550 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12249893 | 0.85 | CYP11B2 (0.32) | CYP11B2 | |
| SCHEMBL2117288 | 0.83 | CYP11B2 (0.30) | CYP11B2 | |
| SCHEMBL12949763 | 0.83 | CYP11B2 (0.30) | CYP11B2 | |
| Hydrochloric Acid SCHEMBL13386437 | 0.82 | — | — | |
| SCHEMBL13386402 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2118094 | 0.80 | KDM4E (0.40) | KDM4ECYP2C19KDM6AKDM4ACYP2C9 | |
| SCHEMBL2117504 | 0.75 | CYP11B2 (0.30) | CYP11B2 | |
| SCHEMBL2118245 | 0.74 | MMP1 (0.33) | COMTCYP11B2 | |
| SCHEMBL12249891 | 0.72 | BRD4 (0.30) | — | |
| SCHEMBL2118349 | 0.72 | APP (0.38) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | claimed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | claimed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| EP-2448922-B1 | FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES | APOTEX TECHNOLOGIES INC (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-8673943-B2 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | KDM4E 946/4885CYP2C19 815/4885KDM6A 630/4885 |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | SLC40A1, TFRC, FECH | KDM4E 946/4885CYP2C19 815/4885KDM6A 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.